Mr. Bologna concluded, "Our quarter-by-quarter results exhibit the work we are doing to turn the Company around and move forward toward success for the benefit of both our patients and our investors. As part of that process, we are pleased to have introduced our Leave No Stone Unturned ResponseDX® marketing program.
For patients testing negative for the ALK Break Apart fluorescence in situ hybridization (FISH) test, we further test those samples with our proprietary PCR-based EML4-ALK test results at minimal cost."Conference Call Details To access the conference call by phone on August 14 at 10:00 a.m. EDT, dial (800) 537-0745 or (253) 237-1142 for international participants. A telephone replay will be available beginning approximately two hours after the call through August 21, 2012, and may be accessed by dialing (855) 859-2056 or (404) 537-3406. The conference passcode for both the live call and replay is 18367261.
To access the live and archived webcast of the conference call, go to the Investor Relations section of the Company's Web site at http://investor.responsegenetics.com. It is advised that participants connect at least 15 minutes prior to the call to allow for any software downloads that might be necessary.
About Response Genetics, Inc.Response Genetics Inc. is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic tests for cancer. The Company's principal customers include oncologists, pathologists and hospitals. In addition to diagnostic testing services, the Company generates revenue from the sales of its analytica
|SOURCE Response Genetics, Inc.|
Copyright©2012 PR Newswire.
All rights reserved